Liposome Formulations for the Strategic Delivery of PARP1 Inhibitors: Development and Optimization

Liposome Formulations for the Strategic Delivery of PARP1 Inhibitors: Development and Optimization

The development of a lipid nano-delivery system was attempted for three specific poly (ADP-ribose) polymerase 1 (PARP1) inhibitors: Veliparib, Rucaparib, and Niraparib. Simple lipid and dual lipid formulations with 1,2-dipalmitoyl-sn-glycero-3-phospho-rac-(1′-glycerol) sodium salt (DPPG) and 1,2-dip...

Full description

Bibliographic Details
Main Authors:	Carlota J. F. Conceição, Elin Moe, Paulo A. Ribeiro, Maria Raposo
Format:	Article
Language:	English
Published:	MDPI AG 2023-05-01
Series:	Nanomaterials
Subjects:	PARP1 inhibitors Veliparib Rucaparib Niraparib liposomes cancer therapy
Online Access:	https://www.mdpi.com/2079-4991/13/10/1613

Similar Items

Hematological Toxicities with PARP Inhibitors in Prostate Cancer: A Systematic Review and Meta-Analysis of Phase II/III Randomized Controlled Trials
by: Gartrell C. Bowling, et al.
Published: (2023-10-01)

Use of First-Line PARP Inhibitors in Ovarian Cancer
by: Ursula Hasler-Strub
Published: (2020-11-01)

Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate Cancer
by: Andrisha-Jade Inderjeeth, et al.
Published: (2022-11-01)

The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review
by: Chien-Hui Lau, et al.
Published: (2022-07-01)

Ki67 as a Predictor of Response to PARP Inhibitors in Platinum Sensitive BRCA Wild Type Ovarian Cancer: The MITO 37 Retrospective Study
by: Valentina Tuninetti, et al.
Published: (2023-02-01)

Evaluation of the Efficacy and Safety of PARP Inhibitors in Advanced-Stage Epithelial Ovarian Cancer
by: Yifan Jiang, et al.
Published: (2020-07-01)

PARP Inhibitors: Strategic Use and Optimal Management in Ovarian Cancer
by: Nicholas Hirschl, et al.
Published: (2024-02-01)

Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer
by: Albert Jang, et al.
Published: (2020-11-01)

LC-MS/MS Method for the Quantification of PARP Inhibitors Olaparib, Rucaparib and Niraparib in Human Plasma and Dried Blood Spot: Development, Validation and Clinical Validation for Therapeutic Drug Monitoring
by: Giovanni Canil, et al.
Published: (2023-05-01)

Differences in PARP Inhibitors for the Treatment of Ovarian Cancer: Mechanisms of Action, Pharmacology, Safety, and Efficacy
by: Giorgio Valabrega, et al.
Published: (2021-04-01)

PARP inhibitor era in ovarian cancer treatment: a systematic review and meta-analysis of randomized controlled trials
by: István Baradács, et al.
Published: (2024-02-01)

Commentary: Adverse event profiles of PARP inhibitors: analysis of spontaneous reports submitted to FAERS
by: Jeanne M. Schilder, et al.
Published: (2023-08-01)

Interactions of PARP1 Inhibitors with PARP1-Nucleosome Complexes
by: Natalya Maluchenko, et al.
Published: (2022-10-01)

Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors
by: Isabella Faraoni, et al.
Published: (2018-12-01)

PARP inhibitor-related haemorrhages: What does the real-world study say?
by: Shiyan Wang, et al.
Published: (2023-02-01)

Maintenance therapy for recurrent epithelial ovarian cancer: current therapies and future perspectives – a review
by: Sudeep Gupta, et al.
Published: (2019-11-01)

The latest first-line treatment options for ovarian cancer: focus on maintenance therapy
by: A. A. Rumyantsev
Published: (2020-12-01)

Incidence and risk of hypertension associated with PARP inhibitors in cancer patients: a systematic review and meta-analysis
by: Xiu Chen, et al.
Published: (2023-01-01)

Anti-tumour and radiosensitising effects of PARP inhibitor on cervical cancer xenografts
by: Qin Xue, et al.
Published: (2023-12-01)

Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer Part 2: Medical Perspectives
by: Stanislas Quesada, et al.
Published: (2022-02-01)

Rucaparib for PARP inhibitor-pretreated ovarian cancer: A GEICO retrospective subgroup analysis from the Spanish Rucaparib Access Program
by: Alfonso Yubero, et al.
Published: (2023-08-01)

PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?
by: Angela Dalia Ricci, et al.
Published: (2020-08-01)

Difluoromethylornithine (DFMO) Enhances the Cytotoxicity of PARP Inhibition in Ovarian Cancer Cells
by: Olivia El Naggar, et al.
Published: (2022-05-01)

Efficacy and safety of veliparib combined with traditional chemotherapy for treating patients with lung cancer: a comprehensive review and meta-analysis
by: Guanhua Zhao, et al.
Published: (2023-11-01)

PARP Inhibitors Display Differential Efficacy in Models of <i>BRCA</i> Mutant High-Grade Serous Ovarian Cancer
by: Kristie-Ann Dickson, et al.
Published: (2021-08-01)

Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer
by: Colombo I, et al.
Published: (2018-03-01)

DNA Repair Enzyme Poly(ADP-Ribose) Polymerase 1/2 (PARP1/2)-Targeted Nuclear Imaging and Radiotherapy
by: Nghia T. Nguyen, et al.
Published: (2022-02-01)

Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain – A GEICO study
by: Alfonso Yubero, et al.
Published: (2022-11-01)

Real‐world data of poly (ADP‐ribose) polymerase inhibitor response in Japanese patients with ovarian cancer
by: Ryosuke Uekusa, et al.
Published: (2024-04-01)

Poly (ADP-Ribose) Polymerase Inhibitor, ABT888, Improved Cisplatin Effect in Human Oral Cell Carcinoma
by: Irene Paterniti, et al.
Published: (2021-07-01)

Preclinical Studies on the Effect of Rucaparib in Ovarian Cancer: Impact of BRCA2 Status
by: Sayeh Saravi, et al.
Published: (2021-09-01)

Comprehensive Analysis of Adverse Events Induced by PARP Inhibitors Using JADER and Time to Onset
by: Kenta Yamaoka, et al.
Published: (2022-08-01)

BRCAness as a Biomarker of Susceptibility to PARP Inhibitors in Glioblastoma Multiforme
by: Mary-Ann Xavier, et al.
Published: (2021-08-01)

IMAGENE trial: multicenter, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy of niraparib with PD-1 inhibitor in solid cancer patients with homologous recombination repair genes mutation
by: Taigo Kato, et al.
Published: (2022-12-01)

PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation
by: Ahrum Min, et al.
Published: (2020-02-01)

First-Line PARP Inhibitors—Emerging Side Effects Require Caution: A Case of PARPi-Induced Pneumonitis
by: Alistair McLaren, et al.
Published: (2021-08-01)

The Current State of the Art in PARP Inhibitor-Based Delivery Nanosystems
by: Lisha Cai, et al.
Published: (2022-08-01)

Privileged Scaffolds for Potent and Specific Inhibitors of Mono-ADP-Ribosylating PARPs
by: Maria Giulia Nizi, et al.
Published: (2023-08-01)

Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors
by: Joline S. J. Lim, et al.
Published: (2017-08-01)

PARP INHIBITORS IN OVARIAN CANCER: TOXICITY PROFILE
by: S. V. KHOKHLOVA, et al.
Published: (2017-06-01)